Hospital
Doctors Hospital of Manteca, INC.
Doctors Hospital of Manteca, INC. was paid $23.54M by Medicaid between Jan 2018 and Dec 2024, across 186 billing codes. Its largest line is 0450, Emergency room services — 54% of everything it billed.
33Billing provider infoDOCTORS HOSPITAL OF MANTECA, INC.
MANTECA, CA 95336
MANTECA, CA 95336
33aNPI1992736599assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.54M
24GClaims381,599
24DCodes billed186
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#109 of 410
Median peer was paid$6.90M
This provider vs. median3.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 94,453 | $4.11M | |
| 2019 | 88,140 | $3.26M | |
| 2020 | 52,461 | $1.92M | |
| 2021 | 32,305 | $2.82M | |
| 2022 | 36,744 | $3.78M | |
| 2023 | 41,849 | $4.25M | |
| 2024incomplete | 35,647 | $3.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 54% | 82,576 | 73,426 | $12.74M |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 3.6% | 10,694 | 9,178 | $848K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 3,166 | 3,060 | $845K |
| C1820 | Generator, neurostimulator (implantable), with rechargeable battery and charging system | 2.8% | 34 | 30 | $671K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 6,462 | 5,830 | $497K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.7% | 7,321 | 7,135 | $400K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.6% | 3,795 | 3,788 | $374K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 2,747 | 2,626 | $320K |
| Z7502 | 1.3% | 8,143 | 7,914 | $305K | |
| 0272 | 1.1% | 5,213 | 4,575 | $266K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 5,653 | 5,073 | $262K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 5,735 | 5,381 | $260K |
174 more codes
| J3490 | Unclassified drugs | 1.1% | 4,454 | $257K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,922 | $233K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,399 | $218K |
| 80053 | Comprehensive metabolic panel | <1% | 18,424 | $212K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,449 | $185K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,910 | $182K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,221 | $180K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,285 | $169K |
| 0360 | <1% | 1,334 | $162K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,123 | $159K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,997 | $142K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,679 | $140K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,571 | $135K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,829 | $113K |
| 76830 | Ultrasound, transvaginal | <1% | 2,021 | $113K |
| 99284 | Emergency room visit (serious) | <1% | 2,035 | $110K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,088 | $109K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,577 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,930 | $94K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,040 | $91K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 19 | $86K |
| 87400 | <1% | 5,896 | $76K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 347 | $73K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 376 | $71K |
| 99283 | Emergency room visit (moderate) | <1% | 1,360 | $69K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,185 | $68K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 991 | $68K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,290 | $65K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,068 | $62K |
| 73562 | <1% | 2,355 | $60K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 442 | $59K |
| 84703 | <1% | 7,500 | $58K | |
| 73030 | <1% | 2,011 | $57K | |
| 73630 | <1% | 2,247 | $56K | |
| 0270 | <1% | 1,949 | $52K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,910 | $51K |
| 84484 | <1% | 5,231 | $50K | |
| 83880 | <1% | 1,890 | $49K | |
| 73610 | <1% | 1,509 | $48K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,815 | $47K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,893 | $45K |
| 83690 | <1% | 6,176 | $43K | |
| J2704 | Injection, propofol, 10 mg | <1% | 311 | $41K |
| 72110 | <1% | 1,178 | $41K | |
| 72100 | <1% | 1,252 | $41K | |
| 0762 | <1% | 43 | $40K | |
| 99285 | Emergency room visit (most serious) | <1% | 668 | $40K |
| 74018 | <1% | 1,418 | $40K | |
| 81001 | <1% | 10,507 | $36K | |
| 0710 | <1% | 1,737 | $35K | |
| 63650 | <1% | 465 | $31K | |
| 87040 | <1% | 2,156 | $31K | |
| V2632 | Posterior chamber intraocular lens | <1% | 118 | $28K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 113 | $28K |
| 73560 | <1% | 924 | $26K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,131 | $26K |
| 87430 | <1% | 2,325 | $25K | |
| 73130 | <1% | 909 | $25K | |
| 75571 | <1% | 423 | $24K | |
| 83605 | <1% | 2,194 | $23K | |
| 80305 | <1% | 1,326 | $23K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,302 | $23K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 474 | $22K |
| 76642 | <1% | 355 | $21K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 836 | $20K |
| 76536 | <1% | 411 | $20K | |
| Z9725 | <1% | 449 | $19K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,523 | $19K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 123 | $19K |
| 29125 | <1% | 70 | $18K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 541 | $18K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,596 | $17K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,213 | $16K |
| 76801 | <1% | 150 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 373 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 988 | $15K |
| 94664 | <1% | 900 | $15K | |
| 0750 | <1% | 87 | $15K | |
| 76770 | <1% | 283 | $15K | |
| 93971 | <1% | 128 | $14K | |
| 73502 | <1% | 480 | $14K | |
| 81003 | <1% | 5,663 | $14K | |
| 73110 | <1% | 589 | $14K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,778 | $14K |
| 76641 | <1% | 141 | $13K | |
| 87186 | <1% | 1,298 | $12K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 83 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 205 | $11K |
| 94060 | <1% | 362 | $11K | |
| 71250 | <1% | 96 | $11K | |
| 85379 | <1% | 991 | $11K | |
| 87077 | <1% | 1,271 | $11K | |
| 72070 | <1% | 444 | $10K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 294 | $10K |
| 83735 | <1% | 1,642 | $10K | |
| 86140 | <1% | 1,737 | $9K | |
| 85610 | <1% | 2,388 | $9K | |
| 84702 | <1% | 611 | $9K | |
| 72050 | <1% | 291 | $8K | |
| 85730 | <1% | 1,473 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 57 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 91 | $8K |
| 72040 | <1% | 212 | $7K | |
| 90715 | <1% | 162 | $7K | |
| 99199 | Unlisted special service, procedure or report | <1% | 142 | $7K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,035 | $7K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 705 | $6K |
| 73221 | <1% | 42 | $6K | |
| 82550 | <1% | 790 | $6K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 56 | $6K |
| 77065 | Tomosynthesis, mammo | <1% | 69 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 793 | $6K |
| 82962 | <1% | 1,827 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 72 | $5K |
| 77066 | Tomosynthesis, mammo | <1% | 39 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 370 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 586 | $4K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 396 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 262 | $4K |
| 73620 | <1% | 132 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 76 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 465 | $4K |
| Z7610 | <1% | 281 | $3K | |
| 63685 | <1% | 52 | $3K | |
| 87420 | <1% | 835 | $3K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 275 | $3K |
| 74178 | <1% | 12 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 339 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 174 | $3K |
| 87631 | <1% | 71 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 281 | $2K |
| 82140 | <1% | 141 | $2K | |
| 77080 | <1% | 74 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 68 | $2K |
| 82150 | <1% | 264 | $2K | |
| 72081 | <1% | 62 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 30 | $2K |
| 71020 | <1% | 54 | $2K | |
| 73140 | <1% | 65 | $1K | |
| 87088 | <1% | 225 | $1K | |
| 72141 | <1% | 12 | $1K | |
| 87070 | <1% | 150 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 103 | $1K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 93 | $1K |
| 59025 | Fetal non-stress test | <1% | 67 | $1K |
| 86901 | <1% | 302 | $948.03 | |
| 86900 | <1% | 302 | $893.60 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 123 | $821.07 |
| 82009 | <1% | 186 | $811.77 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 119 | $769.80 |
| 84100 | <1% | 142 | $708.43 | |
| 81025 | <1% | 116 | $556.27 | |
| 73070 | <1% | 26 | $544.66 | |
| 80299 | <1% | 15 | $535.75 | |
| 71101 | <1% | 13 | $456.25 | |
| 94729 | <1% | 12 | $439.37 | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $396.00 |
| 76870 | <1% | 12 | $394.58 | |
| 82805 | <1% | 13 | $348.68 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 18 | $340.77 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 37 | $327.77 |
| 87210 | <1% | 69 | $317.64 | |
| 73590 | <1% | 15 | $301.74 | |
| 73090 | <1% | 12 | $269.99 | |
| 84439 | <1% | 27 | $166.84 | |
| 82248 | <1% | 26 | $125.54 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $121.03 |
| 87147 | <1% | 15 | $94.65 | |
| 85027 | <1% | 14 | $87.52 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 233 | $84.92 |
| 0250 | <1% | 272 | $65.12 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 193 | $59.30 |
| 36600 | <1% | 12 | $48.85 | |
| 0270R | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGIORGIANI, ROB (CFO)
| Provider | Location | Paid |
|---|---|---|
| Doctors Medical Center of Modesto, INC. | Turlock, CA | $61.42M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.